Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Research Article

Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently

Authors: Sateesh Reddy Nallapalle, Sarika Daripally, V. T. S Vidudala Prasad

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

We investigated risk association of FAS (−1377 G>A and −670 A>G) and FASL (−844 T>C) promoter polymorphisms with breast, ovarian, cervical, and endometrial cancers and report that the FASL −844 CC genotype was protective against breast, ovarian, cervical, and endometrial cancers (P ≤ 0.01). On the other hand, FAS −1377 GA and AA variants increased risk of breast cancer. However, the GA variant of FAS −1377 was also found to be a risk factor for cervical cancer. In contrast, FAS −670 AG variant significantly lowered risk of breast cancer. Further, we also observed that risk association of co-occurrence of FAS and/or FASL variants with the cancers varied as compared to the presence of individual polymorphisms. Although risk and protective haplotypes of FAS SNPs were observed across the cancer phenotypes, the association of the haplotypes was significant for breast cancer alone with a 3-fold enhanced risk. The protective effect of the FASL CC genotype seen in this study suggests that similar biomolecular mechanisms involving FASL might play a role in female-specific cancers.
Literature
1.
2.
Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, et al. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009;29:3977–82.PubMed
3.
4.
Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. Hereditary ovarian cancer clinical study group; the risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7–10.CrossRefPubMed
5.
Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Res Treat. 2011;129:963–9.CrossRefPubMed
6.
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, et al. Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer. 2013;23:1010–5.CrossRefPubMedPubMedCentral
7.
Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58–66.CrossRefPubMed
8.
Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi JL, Kaufmann AM, et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother. 2000;23:67–74.CrossRefPubMed
9.
Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif SN. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006;106:1065–77.CrossRefPubMed
10.
O’Connell J, Bennett MW, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med. 1997;3:294–300.CrossRefPubMedPubMedCentral
11.
O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol. 1998;186:240–6.CrossRefPubMed
12.
13.
Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol. 2000;113:189–94.CrossRefPubMed
14.
Kim Y-S, Kim KH, Choi J-A, Lee JH, Kim HK, Won NH, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas. Arch Pathol Lab Med. 2000;124:687–93.PubMed
15.
Sasaki Y, Hori S, Oda K, Okada T, Takimoto M. Both ETA and ETB receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ETB receptor-deficient rats (aganglionosis rats). Eur J Neurosci. 1998;10:2984–93.CrossRefPubMed
16.
Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.CrossRefPubMed
17.
Zhou JH, Chen HZ, Ye F, Lu WG, Xie X. Fas-mediated pathway and apoptosis in control cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep. 2006;16:307–11.PubMed
18.
Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12:5596–602.CrossRefPubMed
19.
Xu L, Zhou X, Jiang F, Qiu MT, Zhang Z, Yin R, et al. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects. PLoS One. 2013;8:e74543.CrossRefPubMedPubMedCentral
20.
Zhong-Xing Z, Yuan-Yuan M, Hai Zhen M, Jian-Gang Z, Li-Feng Z. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls. PLoS One. 2013;8:e73700.CrossRefPubMedPubMedCentral
21.
Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas gene promoter −670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006;16:179–82.CrossRefPubMed
22.
Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas −1377 A/G and FasL −844 T/C gene polymorphisms epithelial ovarian cancer. Anticancer Res. 2007;27:991–4.PubMed
23.
Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer. 2012;131:716–21.CrossRefPubMed
24.
Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol. 2004;94:25–32.CrossRefPubMed
25.
Newfield L, Bradlow HL, Sepkovic DW, Auborn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. Proc Soc Expt Biol Med. 1998;217:322–6.CrossRef
26.
Jaita G, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, et al. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology. 2005;146:4737–44.CrossRefPubMedPubMedCentral
27.
Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, et al. Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:38–41.PubMed
28.
Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.CrossRefPubMed
29.
Kang S, Dong SM, Seo SS, Kim JW, Park SY. FAS −1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180:1–5.CrossRefPubMed
30.
Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99:113–8.CrossRefPubMed
31.
Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.CrossRefPubMedPubMedCentral
32.
Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.CrossRefPubMedPubMedCentral
33.
Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMed
34.
KordiTamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008;35:183–6.
35.
Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girão MJ, et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009;30:142–4.PubMed
36.
Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92.CrossRefPubMed
37.
Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130:340–5.CrossRefPubMed
38.
Cano A, Serra V, Rivera J, Monmeneu R, Marzo C. Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause. Fertil Steril. 1990;54:1058–64.CrossRefPubMed
39.
Chaudhuri B, Crist KA, Mucci SJ, Thomford NR, Chaudhuri PK. Estrogen receptor in carcinoma in situ of the cervix. J Surg Oncol. 1992;49:103–6.CrossRefPubMed
40.
Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod. 2002;8:447–55.CrossRefPubMed
41.
42.
Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey Jr JV, Cauley JA, et al. Brinton LA; B∼FIT Research Group. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B∼FIT. Carcinogenesis. 2014;35:346–55.CrossRefPubMed
43.
Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013;2:S38–43.CrossRef
44.
Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in control and neoplastic cells. Lab Invest. 1993;69:415–29.PubMed
45.
Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 2014;23:755–64.CrossRefPubMedPubMedCentral
46.
Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25:368–87.CrossRefPubMed
47.
Fambrini M, Buccoliero AM, Pieralli A, Andersson KL, Mattei A, Scarselli G, et al. Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case. Minerva Ginecol. 2011;63:465–70.PubMed
48.
Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012;14:R91.CrossRefPubMedPubMedCentral
49.
Miller S, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:3.
50.
Kriplani A, Banerjee K. An overview of age of onset of menopause in northern India. Maturitas. 2005;52:199–204.CrossRefPubMed
51.
Kapur P, Sinha B, Pereira BM. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause. 2009;16:378–84.CrossRefPubMed
52.
Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.CrossRefPubMed
53.
Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.CrossRefPubMed
54.
Zeng J, Fang Y, Li P. FAS-1377 A/G polymorphism in breast cancer: a meta-analysis. Tumour Biol. 2014;35:2575–81.CrossRefPubMed
55.
Li K, Li W, Zou H, Zhao L. Association between FAS 1377 G>A polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol. 2014;35(1):351–6.CrossRefPubMed
56.
Wang Z, Gu J, Nie W, Xu J, Huang G, Guan X. Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 2014;35:3035–9.CrossRefPubMed
57.
Chen X, Mo W, Peng Q, Su X. Lack of association between Fas rs180082 polymorphisms and risk of cervical cancer: an update by meta-analysis. BMC Med Genet. 2013;14:71.CrossRefPubMedPubMedCentral
58.
Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphisms and cervical cancer risk: evidence from meta-analysis. Tumour Biol. 2014;35:1785–90.CrossRefPubMed
59.
Wang GQ, Bao L, Zhao XX, Zhang J, Nan KJ. Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis. Tumour Biol. 2014;35:4107–12.CrossRefPubMed
60.
Zhu J, Lu L, Cheng X, Xie R, Chen Z, Li Y, et al. Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35:5137–42.CrossRefPubMed
61.
Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, et al. Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case–control study. Leuk Lymphoma. 2012;53:1360–6.CrossRefPubMed
62.
Zhao H, Zheng L, Li X, Wang L. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep. 2014;4:3866.PubMedPubMedCentral
63.
Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008;29:2147–52.CrossRefPubMedPubMedCentral
64.
Lei D, Sturgis EM, Wang LE, Liu Z, Zafereo ME, Wei Q, et al. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2010;19:1484–91.CrossRefPubMedPubMedCentral
65.
Mahfoudh W, Bouaouina N, Gabbouj S. Chouchane. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol. 2012;73:932–8.CrossRefPubMed
66.
Xu Y, Deng Q, He B, Pan Y, Li R, Gao T, et al. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women. Tumour Biol. 2014;35:9147–61.CrossRefPubMed
67.
de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P, et al. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One. 2013;8:e69024.CrossRefPubMedPubMedCentral
68.
Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, et al. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population. In Vivo. 2014;28:397–402.PubMed
69.
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994;54:1580–6.PubMed
70.
Mapara MY, Bargou R, Zugck C, Döhner H, Ustaoglu F, Jonker RR, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol. 1993;23:702–8.CrossRefPubMed
71.
Borset M, Hjorth-Hansen H, Johnsen AC, Seidel C, Waage A, Espevik T, et al. Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol. 1999;63:345–53.CrossRefPubMed
72.
Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006;12:3705–12.CrossRefPubMed
73.
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–43.CrossRefPubMed
74.
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992;267:10709–15.PubMed
75.
Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34:577–82.CrossRefPubMed
76.
Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–30.PubMed
77.
Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas −670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004;112:1084–5.CrossRefPubMed
78.
Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170:132–8.CrossRefPubMed
79.
Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202:967–74.CrossRefPubMedPubMedCentral
80.
Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. J Cancer. 2000;82:1682–8.CrossRef
81.
Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep. 1998;5:377–80.PubMed
82.
Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5:3529–33.PubMed
83.
Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis. 2005;10:1143–9.CrossRefPubMed
84.
Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol. 2000;96:65–9.PubMed
85.
Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29:1183–8.PubMed
86.
Watson CJ, O’Kane H, Maxwell P, Sharaf O, Petak I, Hyland PL, et al. Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer. Int J Oncol. 2012;40:645–54.PubMed
87.
Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, et al. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood. 2012;119:4242–52.CrossRefPubMed
88.
Yurchenko M, Shlapatska LM, Sidorenko SP. The multilevel regulation of CD95 signaling outcome. Exp Oncol. 2012;34:153–9.PubMed
89.
Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle. 2009;8:838–42.CrossRefPubMed
Metadata
Title
Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently
Authors
Sateesh Reddy Nallapalle
Sarika Daripally
V. T. S Vidudala Prasad
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2896-7

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

Epigenetic regulation of human hedgehog interacting protein in glioma cell lines and primary tumor samples

Research Article

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3

Research Article

Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor

Research Article

Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma

Research Article

RETRACTED ARTICLE: Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics

Research Article

Clinical implication of CD166 expression in salivary gland tumor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits